Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > hasta la VI$TA IPO
View:
Post by conspiTheory on Oct 22, 2015 9:02am

hasta la VI$TA IPO

viventia SEC doc

https://www.sec.gov/Archives/edgar/data/1653136/000104746915007972/a2226000zf-1.htm
Comment by givmeabrake on Oct 22, 2015 12:04pm
Interesting! They sure value the need for a solution to Non-Muscle Invasive Bladder Cancer. Their phase II was not as stellar as MCNA's phase II. They are starting phase III this year and require 24 months before evaluation stage MCNA Phase II - 46.4% complete response with 8mg dose at weeks 12 ... VICINIUM Phase II - complete response at the 3-monthly evaluations was achieved ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities